Cyclophilin A基因多态性及其介导的炎症反应在冠心病中的作用
|
摘要
目的：研究cyclophilinA基因多态性及其作为促炎因子在冠状动脉粥样硬化中的作用，并探讨cyclophilinA调控炎症反应的分子机制。
方法：DNA池结合荧光定量PCR技术观察cyclophilinA、TNF-α、IL-6和IL-10各SNP位点多态性与冠心病的相关性。ELISA测定冠心病患者行PCI术前后不同时间段血中cyclophilin A、TNF-α、IL-6和IL-10的水平，观察血中cyclophilin A水平与冠心病炎症状态的相关性。免疫组织化学检测cyclophilin A在冠状动脉粥样硬化斑块和正常组织中的表达差异。Western blot和免疫共沉淀分析在T淋巴细胞中敲除cyclophilinA后对ITK和T-bet表达及活性的影响。
结果：冠心病人cyclophilin A829位点AA型、IL-6797位点AG型和910位点AA型高于正常人，其它位点无明显差异。冠心病患者行PCI术后血中cyclophilin A水平和IL-6、TNF-α逐渐降低，而IL-10水平逐渐升高。CyclophilinA在冠状动脉粥样硬化斑块处高表达，从T细胞中敲除cyclophilin A后，ITK的表达和活性降低，而T-bet表达增加。
结论：
1. CypA829位点的AA基因型突变与冠心病相关。
2. CypA在冠心病人血中水平与冠心病炎症状态呈现正相关性，对PCI术后炎症及术后并发症具有指示作用。
3. CypA通过抑制ITK活性，阻止T细胞向Th2亚型分化，同时促进T-bet的表达，使之向Th1亚型分化，最终加重冠状动脉粥样硬化的炎症程度。
Object To investigate the roles of gene polymorphism and pro-inflammatory activityof cyclophilin A in coronary atherosclerosis, and to explore the mechanisms ofcyclophilin A in inflammatory response.
Methods DNA pool combined with quantitative PCR technique to observe thecorrelation between coronary artery disease and polymorphism of cyclophilin A,TNF-alpha, IL-6and IL-10. ELISA to detect the level of cyclophilin A, TNF-alpha,IL-6and IL-10level before and after percutaneous coronary intervention(PCI) incoronary artery disease(CHD) patients, and observed the correlation betweencyclophilin A level and inflammatory state in coronary artery disease.Immunohistochemical to detect the expression of cyclophilin A in coronaryatherosclerotic plaque and normal tissue. Western blot and coimmunoprecipitation toanalyze the effects of cyclophilin A knock-down on expression of ITK and T-bet in Tlymphocytes.
Results Genotype and allele frequency of the SNP of M829in cyclophilin A gene hasa significant difference between200patients and200controls. Cyclophilin A829AAwas significantly higher than that of healthy controls. Genotype of797A/G and910A/G in IL-6gene was higher than that of healthy controls. There hasn’t significantdifference between200patients and200controls in the allele frequency of the SNP ofTNF-α gene. The levels of cyclophilin A, IL-6and TNF-α were decreased after PCI inCHD, while IL-10levels gradually increased. Cyclophilin A was highly expressed incoronary atherosclerotic plaques. Expression and activity of ITK was declined whenknock-down of cyclophilin A, while T-bet was increased.
Conclusion The polymorphism genotype of cyclophilin A829AA was significantlyhigher than that of healthy controls, may be related to CHD. There was a positivecorrelation between cyclophilin A level and inflammatory state in CHD, cyclophilin Amay be used as a indicator of postoperative inflammation and complications after PCI.Cyclophilin A prevented the differentiation of T cells to Th2subtype by Suppression of ITK activity, while promoting the differentiation to Th1subtype by inducingexpression of T-bet, which aggravated the inflammation in CHD.
方法：DNA池结合荧光定量PCR技术观察cyclophilinA、TNF-α、IL-6和IL-10各SNP位点多态性与冠心病的相关性。ELISA测定冠心病患者行PCI术前后不同时间段血中cyclophilin A、TNF-α、IL-6和IL-10的水平，观察血中cyclophilin A水平与冠心病炎症状态的相关性。免疫组织化学检测cyclophilin A在冠状动脉粥样硬化斑块和正常组织中的表达差异。Western blot和免疫共沉淀分析在T淋巴细胞中敲除cyclophilinA后对ITK和T-bet表达及活性的影响。
结果：冠心病人cyclophilin A829位点AA型、IL-6797位点AG型和910位点AA型高于正常人，其它位点无明显差异。冠心病患者行PCI术后血中cyclophilin A水平和IL-6、TNF-α逐渐降低，而IL-10水平逐渐升高。CyclophilinA在冠状动脉粥样硬化斑块处高表达，从T细胞中敲除cyclophilin A后，ITK的表达和活性降低，而T-bet表达增加。
结论：
1. CypA829位点的AA基因型突变与冠心病相关。
2. CypA在冠心病人血中水平与冠心病炎症状态呈现正相关性，对PCI术后炎症及术后并发症具有指示作用。
3. CypA通过抑制ITK活性，阻止T细胞向Th2亚型分化，同时促进T-bet的表达，使之向Th1亚型分化，最终加重冠状动脉粥样硬化的炎症程度。
Object To investigate the roles of gene polymorphism and pro-inflammatory activityof cyclophilin A in coronary atherosclerosis, and to explore the mechanisms ofcyclophilin A in inflammatory response.
Methods DNA pool combined with quantitative PCR technique to observe thecorrelation between coronary artery disease and polymorphism of cyclophilin A,TNF-alpha, IL-6and IL-10. ELISA to detect the level of cyclophilin A, TNF-alpha,IL-6and IL-10level before and after percutaneous coronary intervention(PCI) incoronary artery disease(CHD) patients, and observed the correlation betweencyclophilin A level and inflammatory state in coronary artery disease.Immunohistochemical to detect the expression of cyclophilin A in coronaryatherosclerotic plaque and normal tissue. Western blot and coimmunoprecipitation toanalyze the effects of cyclophilin A knock-down on expression of ITK and T-bet in Tlymphocytes.
Results Genotype and allele frequency of the SNP of M829in cyclophilin A gene hasa significant difference between200patients and200controls. Cyclophilin A829AAwas significantly higher than that of healthy controls. Genotype of797A/G and910A/G in IL-6gene was higher than that of healthy controls. There hasn’t significantdifference between200patients and200controls in the allele frequency of the SNP ofTNF-α gene. The levels of cyclophilin A, IL-6and TNF-α were decreased after PCI inCHD, while IL-10levels gradually increased. Cyclophilin A was highly expressed incoronary atherosclerotic plaques. Expression and activity of ITK was declined whenknock-down of cyclophilin A, while T-bet was increased.
Conclusion The polymorphism genotype of cyclophilin A829AA was significantlyhigher than that of healthy controls, may be related to CHD. There was a positivecorrelation between cyclophilin A level and inflammatory state in CHD, cyclophilin Amay be used as a indicator of postoperative inflammation and complications after PCI.Cyclophilin A prevented the differentiation of T cells to Th2subtype by Suppression of ITK activity, while promoting the differentiation to Th1subtype by inducingexpression of T-bet, which aggravated the inflammation in CHD.
引文
1. Buja L M, Kita T, Goldstein J L, Watanabe Y, Brown M S. Cellular pathology ofprogressive atherosclerosis in the WHHL rabbit. An animal modelof familial hypercholesterolemia [J]. Arteriosclerosis1983;3(1):87-101.
2. Narayanaswamy M, Wright K C, Kandarpa K. Animal models foratherosclerosis, restenosis, and endovascular graft research [J]. J Vasc IntervRadiol2000;11(1):5-17.
3. Chiesa q Hobbs H H, Koschinsky M L, Lawn R M, Maika S D, Hammer R E.Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein intotransgenic mice expressing human apolipoprotein(a)[J]. The Journalof biological chemistry1992;267(34):24369-24374.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the1990s [J].Nature1993;362(6423):801-809.
5. Lusis A J. Atherosclerosis [J]. Nature2000;407(6801):233-241.
6. Antonicelli R，Olivieri F，Bonafè M，et al.The interleukin-6-174G/C promoterpolymorphism is associated with a higher risk of death after an acute coronarysyndrome in male elderly patients.Int J Cardiol，2005，103(3):266-271.
7. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW.Cyclophilin: aspecific cytosolic binding protein for cyclosporin A. Science,1984,226(4674):544-547
8. Gasser CS, Gunning DA, Budelier KA, Brown SM. Structure and expressionof cytosolic cyclophilin/peptidyl2prolyl cis2trans isomerase of higher plants andproduction of active tomato cyclophilin in Escherichia coli. Proc Natl AcadSci USA,1990,87(24):519-523
9. Ma Iaguarnera M,Trovato Ba，Laurino A,et al.Interleukin-6in hepatitis Cfibrosis.Panminerva Med，996,38(4):207.
10. Hamid YH，Rose CS，Urhammer SA，et al.Variations of the interleukin-6promoter are associated with features of the metabolic syndrome in caucasiandanes.Diabetologia，2005，48(2)：215-260.
11. Fu HX，Li GS，Li Y，et al.Interleukin-6-597G/A and-572C/G polymorphisms andrisk of coronary heart disease.中华心血管病杂志，2006，34(6):519-522.
12.韦叶生,唐任光,等.冠心病患者白细胞介素-6血清水平检测的临床意义.陕西医学杂志，2005，8(8)：907-909.
13. Cox ED，Hofference SC，Dimercurio BS，et al.Cytokine polymorphic analysesindicate ethnic differencein the allelic distribution of interleukin-2andinterleukin-6.Transplantation,2001，72(4)：720-726.
14. Lim CS,Zheng S,Kim YS.The-174G to C polymorphism of interleukin-6genevery rare in koreans.Cytokine,2002,19(1):52-54.
15. Terry CF,Loukac IV,Green FR.Cooperative influence of genetic polymorphismson interleukin-6transcriptional regulation.J Biol Chem,2000,275:18138-18144.
16. Foster CB，Lehrenbecher T，Samuels S，et al.An IL-6promoter polymorphism isassociated with a lifetime risk of development Kaposisarcoma in man infectedwith human immunodeficiency virus.Blood，2000，96(7)：2562-2567.
17. Sekuri C，Cam FS，Sagcan A，et al.No association of interleukin-6genepolymorphism(-174G/C)with premature coronary artery disease in a Turkishcohort.Coron Artery Dis，2007，18(5):333-337.
18.杨超，李艳，张平安，等.冠心病患者白细胞介素-6基因-174G/C的多态性研究.四川医学,2004,25(4):404-406.
19. Fu HX，Li GS，Li Y，et al.Interleukin-6-597G/A and-572C/G polymorphisms andrisk of coronary heart disease.中华心血管病杂志，2006，34(6):519-522.
20. Kitamura A，Hasegawa G,Obayashi H，et al.Interleukin-6polymorphism(-634C/G)in the promotor region and the progression of diabetic nephropathy in type2diabetes.Diabetes Med,2002,19(12):1000-1005.
21. Jang Y， Kim OY， Hyun YJ， et al.Interleukin-6-572C/Gpolymorphism association with inflammatory variables in Korean men withcoronary artery disease.Transl Res，2008151(3):154-161.
22.12Fu HX，Li GS，Li Y，et al.Interleukin-6-597G/A and-572C/G polymorphismsand risk of coronary heart disease.中华心血管病杂志，2006，34(6):519-522.
23. Nakajima T，Ota N,Yoshida H,et al.Allelic variants in the interleukin-6gene andessential hypertension in Japanese women.Genes and Immuninty，1999,1:115-119.
1. P. Nigro, K. Satoh, M.R. O'Dell, N.N. Soe, Z. Cui, A. Mohan, J.-i. Abe, J.D.Alexis, J.D. Sparks, and B.C. Berk, Cyclophilin A is an inflammatory mediatorthat promotes atherosclerosis in apolipoprotein E-deficient mice. J. Exp. Med.2011Jan17;208(1):53-66.
2.白如冰,宋晓丽, PCI术对冠心病患者血小板活性物质CD41、CD61水平的影响.亚太传统医药.2011年第3期87-88.
3.陈丹,黄仑,尚怡君,急性心肌梗死直接PCI联合静脉应用重组人脑利钠肽对左心室重构和功能的影响.吉林医学.2011年第1期11-13.
4.陈志刚,黄陆力,张永春, PCI对冠心病并发室性心律失常的影响.医学信息(上旬刊).2011年第7期1967-1968.
5.郭青榜,关瑞锦, PCI相关心肌梗死的临床研究进展.医学信息(上旬刊).2011年第7期2166-2167
6.侯凤霞,靳朝辉,杨德琼,高龄老年急性冠脉综合征患者PCI治疗疗效及联合抗血小板治疗的安全性.中国老年学杂志.2011年第1期17-19.
7.黄仑,牛晓明,赵良辰,张杨,王冰,利钠肽在心肌梗死PCI术后的心脏保护作用.吉林医学.2011年第4期740-742.
8.周四桂,徐立朋,廖端芳,雷小勇,严奉祥,朱炳阳,环孢霉素A通过ROS-Cyclophilin A-ERK1/2信号途径抑制人脐静脉内皮细胞与中性粒细胞粘附.生理学报2004年第3期313-320.
9. M. Arevalo-Rodriguez, and J. Heitman, Cyclophilin A Is Localized to the Nucleusand Controls Meiosis in Saccharomyces cerevisiae. Eukaryot. Cell2005;4(1):17–29.
10. S. J, M. DF, M. T, B. BC,谢闵, Cyclophilin A在血管平滑肌细胞中经囊状途径分泌.中国动脉硬化杂志2006年第5期394-394.
11.曹春芽,黄红林,亲环素A在心血管系统中的作用.南华大学学报(医学版)2006年第5期650-653
12.崔建美,王宇,王燕,王培育,刘艳艳,杨永清, Cyclophilin A的功能研究进展.免疫学杂志2006年第z1期47-50.
13.赵雅琳孙奡燕姚宇,急性心肌梗死患者PCI后NT-proBNP、hs—CRP水平变化及意义.《山东医药》2012年第3期102-103.
14.杨模国,阿托伐他汀对不稳定性心绞痛PCI术后炎症因子的影响.《中国现代医生》2008年第20期33-35.
15.罗伟俊,季乃军,胡昌盛,李付远,陈东海,童丽军,梅益斌,急性冠脉综合征患者血清内皮素-1与C反应蛋白的变化及PCI的影响观察.心脑血管病防治2011年第1期32-34.
16.梁伟东曾波,阿托伐他汀对急性冠脉综合征患者血清内皮素和血管细胞黏附分子-1的影响.《现代预防医学》2010年第12期2373-2374.
17.戎梦瑶,朵瑞雪,朱平,王聪华,汪莉,樊春梅,王彦宏,细胞亲环素A对单核来源泡沫细胞功能的影响.细胞与分子免疫学杂志2011年第5期515-518.
18.王朝富,王培书,彭超,刘全义,一次性阿托伐他汀强化治疗对急性冠脉综合征患者PCI术后血清hs-CRP和MMP-9水平的影响.实用医学杂志2011年第3期488-490.
19.张田田,张俊峰,亲环素A及其受体CD147对动脉粥样硬化的影响.上海交通大学学报(医学版)2011年第12期1778-1781.
20.葛良清周怀能,替罗非班对急性冠脉综合征患者PCI术后心功能及炎症因子的影响.《中国现代医学杂志》2011年第30期3834-3836.
21. J.W. Dear, K.J. Simpson, M.P.J. Nicolai, J.H. Catterson, J. Street, T. Huizinga,D.G. Craig, K. Dhaliwal, S. Webb, D.N. Bateman, and D.J. Webb, Cyclophilin AIs a Damage-Associated Molecular Pattern Molecule That MediatesAcetaminophen-Induced Liver Injury. J Immunol.2011;187(6):3347-52.
22.周波,罗玉萍,龚熹,李思光,亲环蛋白的结构、细胞定位和生物学功能.细胞生物学杂志2008年第3期291-296.
23.郭琰,廖端芳,庹勤慧, Cyclophilin A在心脑血管疾病方面的研究进展.现代生物医学进展2009年第17期3384-3386.
24. C. Zhu, X. Wang, J. Deinum, Z. Huang, J. Gao, N. Modjtahedi, M.R. Neagu, M.Nilsson, P.S. Eriksson, H. Hagberg, J. Luban, G. Kroemer, and K. Blomgren,Cyclophilin A participates in the nuclear translocation of apoptosis-inducingfactor in neurons after cerebral hypoxia-ischemia. J Exp Med.2007;204:1741–1748.
25. K. Satoh, T. Matoba, J. Suzuki, M.R. O'Dell, P. Nigro, Z. Cui, A. Mohan, S. Pan,L. Li, Z.-G. Jin, C. Yan, J.-i. Abe, and B.C. Berk, Cyclophilin A MediatesVascular Remodeling by Promoting Inflammation and Vascular Smooth MuscleCell Proliferation. Circulation.2008;117(24):3088-98.
26.郭紫芬,廖端芳, Cyclophilin A触发荷脂细胞免疫反应与胆固醇跨膜转运的关系.中国动脉硬化杂志2009年第7期615.
27.何瑾,周志刚,王春燕,尹凯,孟军,涂玉林,亲环素A在ox-LDL诱导的血管平滑肌细胞泡沫化过程中的作用.南华大学学报(医学版)(2009).
28.廖端芳,庹勤慧,郭琰, Cyclophilin A通过调控炎症/免疫反应介导动脉粥样硬化.中国动脉硬化杂志2009年第7期614-614.
1. N. Nagradova, Peptidyl-prolyl Cis/trans Isomerase Activity In The FunctioningOf Native Folded Proteins. WebmedCentral MOLECULAR BIOLOGY1WMC00965.
2. D. Fruman, C. Klee, B. Bierer, and S. Burakoff, Calcineurin Phosphatase Activityin T Lymphocytes is Inhibited by FK506and Cyclosporin A. PNAS89(1992)3686-3690.
3. W. Rosamond, K. Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. Haase, M.Ho, V. Howard, B. Kissela, S. Kittner, D. Lloyd-Jones, M. McDermott, J. Meigs,C. Moy, G. Nichol, C.J. O'Donnell, V. Roger, J. Rumsfeld, P. Sorlie, J. Steinberger,T. Thom, S. Wasserthiel-Smoller, Y. Hong, f.t.A.H.A.S. Committee, and StrokeStatistics Subcommittee, Heart Disease and Stroke Statistics--2007Update: AReport From the American Heart Association Statistics Committee and StrokeStatistics Subcommittee. Circulation115(2007) e69-171.
4. R. Ross, Atherosclerosis--An Inflammatory Disease. N. Engl. J. Med.340(1999)115-126.
5. J. Liu, J. Farmer, W. Lane, J. Friedman, I. Weissman, and S. Schreiber,Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506complexes. Cell66(1991)807-15.
6. Galat, Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem216(1993)689-707.
7. Sherry, N. Yarlett, A. Strupp, and A. Cerami, Identification of Cyclophilin as aProinflammatory Secretory Product of Lipopolysaccharide-ActivatedMacrophages. PNAS89(1992)3511-3515.
8. Q. Xu, M. Leiva, S. Fischkoff, R. Handschumacher, and C. Lyttle, Leukocytechemotactic activity of cyclophilin. J. Biol. Chem.267(1992)11968-11971.
9. J. Rengarajan, S. Szabo, and L. Glimcher, Transcriptional regulation of Th1/Th2polarization. Immunol Today21(2000)479-83.
10. Miller, H. Wilcox, Z. Lai, and L. Berg, Signaling through Itk promotes T helper2differentiation via negative regulation of T-bet. Immunity21(2004)67-80.
11. J. Kofron, P. Kuzmic, V. Kishore, E. Colon-Bonilla, and D. Rich, Determinationof kinetic constants for peptidyl prolyl cis-trans isomerases by an improvedspectrophotometric assay. Biochemistry30(1991)6127-34.
12. J. Frostegard, A. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson, andG. Hansson, Cytokine expression in advanced human atherosclerotic plaques:dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.Atherosclerosis145(1999)33-43.
13. E.S. Hwang, S.J. Szabo, P.L. Schwartzberg, and L.H. Glimcher, T Helper CellFate Specified by Kinase-Mediated Interaction of T-bet with GATA-3. Science307(2005)430-433.
14. R. Mallis, K. Brazin, D. Fulton, and A. Andreotti, Structural characterization of aproline-driven conformational switch within the Itk SH2domain. Nat Struct Biol9(2002)900-5.
1. Girn HR, Orsi NM, Homer-Vanniasinkam S. An overview of cytokineinteractions in atherosclerosis and implications for peripheral arterial disease.Vasc Med2007;12(4):299-309.
2. Dinarello CA. The role of the interleukin-1-receptor antagonist in blockinginflammation mediated by interleukin-1. N Engl J Med2000;343(10):732-734.
3. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differentialeffects of interleukin-1receptor antagonist and tumor necrosis factor bindingprotein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation1998;97(3):242-244.
4. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, JamesRW, Mach F, Gabay C. Interleukin-1plays a major role in vascular inflammationand atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res2005;66(3):583-593.
5. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y,Ohsuzu F. Lack of interleukin-1receptor antagonist modulates plaquecomposition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol2004;24(6):1068-1073.
6. Isoda K, Ohsuzu F. The effect of interleukin-1receptor antagonist on arteries andcholesterol metabolism. J Atheroscler Thromb2006;13(1):21-30.
7. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18enhancesatherosclerosis in apolipoprotein E(-/-) mice through release ofinterferon-gamma. Circ Res2002;90(2):E34-38.
8. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, Bayard F,Hansson GK. Reduced atherosclerosis in interleukin-18deficient apolipoproteinE-knockout mice. Cardiovasc Res2003;59(1):234-240.
9. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y,Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18binding protein signalingmodulates atherosclerotic lesion development and stability. Circ Res2001;89(7):E41-45.
10. Upadhya S, Mooteri S, Peckham N, Pai RG. Atherogenic effect of interleukin-2and antiatherogenic effect of interleukin-2antibody in apo-E-deficient mice.Angiology2004;55(3):289-294.
11. Walch L, Massade L, Dufilho M, Brunet A, Rendu F. Pro-atherogenic effect ofinterleukin-4in endothelial cells: modulation of oxidative stress, nitric oxide andmonocyte chemoattractant protein-1expression. Atherosclerosis2006;187(2):285-291.
12. George J, Mulkins M, Shaish A, Casey S, Schatzman R, Sigal E, Harats D.Interleukin (IL)-4deficiency does not influence fatty streak formation inC57BL/6mice. Atherosclerosis2000;153(2):403-411.
13. Davenport P, Tipping PG. The role of interleukin-4and interleukin-12in theprogression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol2003;163(3):1117-1125.
14. Vadiveloo PK, Stanton HR, Cochran FW, Hamilton JA. Interleukin-4inhibitshuman smooth muscle cell proliferation. Artery1994;21(3):161-181.
15. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA. Stat6activationis essential for interleukin-4induction of P-selectin transcription in humanumbilical vein endothelial cells. Arterioscler Thromb Vasc Biol1999;19(6):1421-1429.
16. King VL, Cassis LA, Daugherty A. Interleukin-4does not influence developmentof hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice.Am J Pathol2007;171(6):2040-2047.
17. George J, Shoenfeld Y, Gilburd B, Afek A, Shaish A, Harats D. Requisite role forinterleukin-4in the acceleration of fatty streaks induced by heat shock protein65or Mycobacterium tuberculosis. Circ Res2000;86(12):1203-1210.
18. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: acomprehensive review of studies in mice. Cardiovasc Res2008;79(3):360-376.
19. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, CurtissLK, Corr M, Witztum JL. IL-5links adaptive and natural immunity specific forepitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest2004;114(3):427-437.
20. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM,Lusis AJ. Induction of endothelial cell expression of granulocyte andmacrophage colony-stimulating factors by modified low-density lipoproteins.Nature1990;344(6263):254-257.
21. Shaposhnik Z, Wang X, Weinstein M, Bennett BJ, Lusis AJ. Granulocytemacrophage colony-stimulating factor regulates dendritic cell content ofatherosclerotic lesions. Arterioscler Thromb Vasc Biol2007;27(3):621-627.
22. Shindo J, Ishibashi T, Yokoyama K, Nakazato K, Ohwada T, Shiomi M,Maruyama Y. Granulocyte-macrophage colony-stimulating factor prevents theprogression of atherosclerosis via changes in the cellular and extracellularcomposition of atherosclerotic lesions in watanabe heritable hyperlipidemicrabbits. Circulation1999;99(16):2150-2156.
23. Haghighat A, Weiss D, Whalin MK, Cowan DP, Taylor WR. Granulocytecolony-stimulating factor and granulocyte macrophage colony-stimulating factorexacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation2007;115(15):2049-2054.
24. Ditiatkovski M, Toh BH, Bobik A. GM-CSF deficiency reduces macrophagePPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice.Arterioscler Thromb Vasc Biol2006;26(10):2337-2344.
25. Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A, Lambert D,Visvikis S. IL-6, TNF-α-alpha and atherosclerosis risk indicators in a healthyfamily population: the STANISLAS cohort. Atherosclerosis2003;170(2):277-283.
26. von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins inatherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev2003;55(1):133-166.
27. Klouche M, Rose-John S, Schmiedt W, Bhakdi S. Enzymatically degraded,nonoxidized LDL induces human vascular smooth muscle cell activation, foamcell transformation, and proliferation. Circulation2000;101(15):1799-1805.
28. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6exacerbatesearly atherosclerosis in mice. Arterioscler Thromb Vasc Biol1999;19(10):2364-2367.
29. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F.Involvement of interleukin-6in atherosclerosis but not in the prevention of fattystreak formation by17beta-estradiol in apolipoprotein E-deficient mice.Atherosclerosis2001;156(2):315-320.
30. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ,Trautwein C, Luchtefeld M, Schmittkamp C, Heeneman S, Daemen MJ, DrexlerH. Impact of interleukin-6on plaque development and morphology inexperimental atherosclerosis. Circulation2004;110(22):3493-3500.
31. Song L, Schindler C. IL-6and the acute phase response in murine atherosclerosis.Atherosclerosis2004;177(1):43-51.
32. Trinchieri G. Interleukin-12and the regulation of innate resistance and adaptiveimmunity. Nat Rev Immunol2003;3(2):133-146.
33. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, vanSnick J, Kuiper J. Blockade of interleukin-12function by protein vaccinationattenuates atherosclerosis. Circulation2005;112(7):1054-1062.
34. Baidya SG, Zeng QT, Wang X, Guo HP. T helper cell related interleukins and theangiographic morphology in unstable angina. Cytokine2005;30(5):303-310.
35. Steppich BA, Moog P, Matissek C, Wisniowski N, Kuhle J, Joghetaei N,Neumann FJ, Schomig A, Ott I. Cytokine profiles and T cell function in acutecoronary syndromes. Atherosclerosis2007;190(2):443-451.
36. Harvey EJ, Ramji DP. Interferon-gamma and atherosclerosis: pro-oranti-atherogenic? Cardiovasc Res2005;67(1):11-20.
37. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatorypathways. Physiol Rev2006;86(2):515-581.
38. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, Kim DW, Kim YK, RoHK, Shong M. Statin inhibits interferon-gamma-induced expression ofintercellular adhesion molecule-1(ICAM-1) in vascular endothelial and smoothmuscle cells. Exp Mol Med2002;34(6):451-461.
39. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gammaenhances atherosclerosis in apolipoprotein E-/-mice. Am J Pathol2000;157(6):1819-1824.
40. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exertsgender-specific effects on atherogenesis in apolipoprotein E-/-mice. J InterferonCytokine Res2002;22(6):661-670.
41. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH.Influence of interferon-gamma on the extent and phenotype of diet-inducedatherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol2003;23(3):454-460.
42. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gammapotentiates atherosclerosis in ApoE knock-out mice. J Clin Invest1997;99(11):2752-2761.
43. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detectionand localization of tumor necrosis factor in human atheroma. Am J Cardiol1990;65(5):297-302.
44. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis ofatherosclerosis. Thromb Haemost2002;88(4):554-567.
45. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhancedexpression of vascular matrix metalloproteinases induced in vitro by cytokinesand in regions of human atherosclerotic lesions. Ann N Y Acad Sci1995;748:501-507.
46. Schreyer SA, Vick CM, LeBoeuf RC. Loss of lymphotoxin-alpha but not tumornecrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem2002;277(14):12364-12368.
47. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, Saito K, Sekikawa K,Seishima M. Disruption of tumor necrosis factor-alpha gene diminishes thedevelopment of atherosclerosis in ApoE-deficient mice. Atherosclerosis2005;180(1):11-17.
48. Boesten LS, Zadelaar AS, van Nieuwkoop A, Gijbels MJ, de Winther MP,Havekes LM, van Vlijmen BJ. Tumor necrosis factor-alpha promotesatherosclerotic lesion progression in APOE*3-Leiden transgenic mice.Cardiovasc Res2005;66(1):179-185.
49. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in micelacking tumor necrosis factor receptor p55. J Biol Chem1996;271(42):26174-26178.
50. Shin WS, Szuba A, Rockson SG. The role of chemokines in humancardiovascular pathology: enhanced biological insights. Atherosclerosis2002;160(1):91-102.
51. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease.Circ Res2004;95(9):858-866.
52. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue ofthe IL-8receptor CXCR-2mediates the accumulation of macrophages inatherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest1998;101(2):353-363.
53. Martins TB, Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Roberts WL.Risk factor analysis of plasma cytokines in patients with coronary artery diseaseby a multiplexed fluorescent immunoassay. Am J Clin Pathol2006;125(6):906-913.
54. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8mediates downregulation of tissue inhibitor of metalloproteinase-1expression incholesterol-loaded human macrophages: relevance to stability of atheroscleroticplaque. Circulation1999;99(3):420-426.
55. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F,Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A.Protective role of interleukin-10in atherosclerosis. Circ Res1999;85(8):e17-24.
56. Namiki M, Kawashima S, Yamashita T, Ozaki M, Sakoda T, Inoue N, Hirata K,Morishita R, Kaneda Y, Yokoyama M. Intramuscular gene transfer ofinterleukin-10cDNA reduces atherosclerosis in apolipoprotein E-knockout mice.Atherosclerosis2004;172(1):21-29.
57. Anguera I, Miranda-Guardiola F, Bosch X, Filella X, Sitges M, Marin JL, BetriuA, Sanz G. Elevation of serum levels of the anti-inflammatory cytokineinterleukin-10and decreased risk of coronary events in patients with unstableangina. Am Heart J2002;144(5):811-817.
58. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of theantiinflammatory cytokine interleukin-10are decreased in patients with unstableangina. Circulation2001;104(7):746-749.
59. Metcalfe JC, Grainger DJ. Transforming growth factor-beta and the protectionfrom cardiovascular injury hypothesis. Biochem Soc Trans1995;23(2):403-406.
60. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, sogood for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol2004;24(3):399-404.
61. Yamagami S, Yokoo S, Mimura T, Amano S. Effects of TGF-beta2on immuneresponse-related gene expression profiles in the human corneal endothelium.Invest Ophthalmol Vis Sci2004;45(2):515-521.
62. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB,Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta1nullmutation in mice causes excessive inflammatory response and early death. ProcNatl Acad Sci U S A1993;90(2):770-774.
63. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R,Fradelizi D, Tedgui A. Inhibition of transforming growth factor-beta signalingaccelerates atherosclerosis and induces an unstable plaque phenotype in mice.Circ Res2001;89(10):930-934.
64. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE,Daemen MJ. Transforming growth factor-beta mediates balance betweeninflammation and fibrosis during plaque progression. Arterioscler Thromb VascBiol2002;22(6):975-982.
2. Narayanaswamy M, Wright K C, Kandarpa K. Animal models foratherosclerosis, restenosis, and endovascular graft research [J]. J Vasc IntervRadiol2000;11(1):5-17.
3. Chiesa q Hobbs H H, Koschinsky M L, Lawn R M, Maika S D, Hammer R E.Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein intotransgenic mice expressing human apolipoprotein(a)[J]. The Journalof biological chemistry1992;267(34):24369-24374.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the1990s [J].Nature1993;362(6423):801-809.
5. Lusis A J. Atherosclerosis [J]. Nature2000;407(6801):233-241.
6. Antonicelli R，Olivieri F，Bonafè M，et al.The interleukin-6-174G/C promoterpolymorphism is associated with a higher risk of death after an acute coronarysyndrome in male elderly patients.Int J Cardiol，2005，103(3):266-271.
7. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW.Cyclophilin: aspecific cytosolic binding protein for cyclosporin A. Science,1984,226(4674):544-547
8. Gasser CS, Gunning DA, Budelier KA, Brown SM. Structure and expressionof cytosolic cyclophilin/peptidyl2prolyl cis2trans isomerase of higher plants andproduction of active tomato cyclophilin in Escherichia coli. Proc Natl AcadSci USA,1990,87(24):519-523
9. Ma Iaguarnera M,Trovato Ba，Laurino A,et al.Interleukin-6in hepatitis Cfibrosis.Panminerva Med，996,38(4):207.
10. Hamid YH，Rose CS，Urhammer SA，et al.Variations of the interleukin-6promoter are associated with features of the metabolic syndrome in caucasiandanes.Diabetologia，2005，48(2)：215-260.
11. Fu HX，Li GS，Li Y，et al.Interleukin-6-597G/A and-572C/G polymorphisms andrisk of coronary heart disease.中华心血管病杂志，2006，34(6):519-522.
12.韦叶生,唐任光,等.冠心病患者白细胞介素-6血清水平检测的临床意义.陕西医学杂志，2005，8(8)：907-909.
13. Cox ED，Hofference SC，Dimercurio BS，et al.Cytokine polymorphic analysesindicate ethnic differencein the allelic distribution of interleukin-2andinterleukin-6.Transplantation,2001，72(4)：720-726.
14. Lim CS,Zheng S,Kim YS.The-174G to C polymorphism of interleukin-6genevery rare in koreans.Cytokine,2002,19(1):52-54.
15. Terry CF,Loukac IV,Green FR.Cooperative influence of genetic polymorphismson interleukin-6transcriptional regulation.J Biol Chem,2000,275:18138-18144.
16. Foster CB，Lehrenbecher T，Samuels S，et al.An IL-6promoter polymorphism isassociated with a lifetime risk of development Kaposisarcoma in man infectedwith human immunodeficiency virus.Blood，2000，96(7)：2562-2567.
17. Sekuri C，Cam FS，Sagcan A，et al.No association of interleukin-6genepolymorphism(-174G/C)with premature coronary artery disease in a Turkishcohort.Coron Artery Dis，2007，18(5):333-337.
18.杨超，李艳，张平安，等.冠心病患者白细胞介素-6基因-174G/C的多态性研究.四川医学,2004,25(4):404-406.
19. Fu HX，Li GS，Li Y，et al.Interleukin-6-597G/A and-572C/G polymorphisms andrisk of coronary heart disease.中华心血管病杂志，2006，34(6):519-522.
20. Kitamura A，Hasegawa G,Obayashi H，et al.Interleukin-6polymorphism(-634C/G)in the promotor region and the progression of diabetic nephropathy in type2diabetes.Diabetes Med,2002,19(12):1000-1005.
21. Jang Y， Kim OY， Hyun YJ， et al.Interleukin-6-572C/Gpolymorphism association with inflammatory variables in Korean men withcoronary artery disease.Transl Res，2008151(3):154-161.
22.12Fu HX，Li GS，Li Y，et al.Interleukin-6-597G/A and-572C/G polymorphismsand risk of coronary heart disease.中华心血管病杂志，2006，34(6):519-522.
23. Nakajima T，Ota N,Yoshida H,et al.Allelic variants in the interleukin-6gene andessential hypertension in Japanese women.Genes and Immuninty，1999,1:115-119.
1. P. Nigro, K. Satoh, M.R. O'Dell, N.N. Soe, Z. Cui, A. Mohan, J.-i. Abe, J.D.Alexis, J.D. Sparks, and B.C. Berk, Cyclophilin A is an inflammatory mediatorthat promotes atherosclerosis in apolipoprotein E-deficient mice. J. Exp. Med.2011Jan17;208(1):53-66.
2.白如冰,宋晓丽, PCI术对冠心病患者血小板活性物质CD41、CD61水平的影响.亚太传统医药.2011年第3期87-88.
3.陈丹,黄仑,尚怡君,急性心肌梗死直接PCI联合静脉应用重组人脑利钠肽对左心室重构和功能的影响.吉林医学.2011年第1期11-13.
4.陈志刚,黄陆力,张永春, PCI对冠心病并发室性心律失常的影响.医学信息(上旬刊).2011年第7期1967-1968.
5.郭青榜,关瑞锦, PCI相关心肌梗死的临床研究进展.医学信息(上旬刊).2011年第7期2166-2167
6.侯凤霞,靳朝辉,杨德琼,高龄老年急性冠脉综合征患者PCI治疗疗效及联合抗血小板治疗的安全性.中国老年学杂志.2011年第1期17-19.
7.黄仑,牛晓明,赵良辰,张杨,王冰,利钠肽在心肌梗死PCI术后的心脏保护作用.吉林医学.2011年第4期740-742.
8.周四桂,徐立朋,廖端芳,雷小勇,严奉祥,朱炳阳,环孢霉素A通过ROS-Cyclophilin A-ERK1/2信号途径抑制人脐静脉内皮细胞与中性粒细胞粘附.生理学报2004年第3期313-320.
9. M. Arevalo-Rodriguez, and J. Heitman, Cyclophilin A Is Localized to the Nucleusand Controls Meiosis in Saccharomyces cerevisiae. Eukaryot. Cell2005;4(1):17–29.
10. S. J, M. DF, M. T, B. BC,谢闵, Cyclophilin A在血管平滑肌细胞中经囊状途径分泌.中国动脉硬化杂志2006年第5期394-394.
11.曹春芽,黄红林,亲环素A在心血管系统中的作用.南华大学学报(医学版)2006年第5期650-653
12.崔建美,王宇,王燕,王培育,刘艳艳,杨永清, Cyclophilin A的功能研究进展.免疫学杂志2006年第z1期47-50.
13.赵雅琳孙奡燕姚宇,急性心肌梗死患者PCI后NT-proBNP、hs—CRP水平变化及意义.《山东医药》2012年第3期102-103.
14.杨模国,阿托伐他汀对不稳定性心绞痛PCI术后炎症因子的影响.《中国现代医生》2008年第20期33-35.
15.罗伟俊,季乃军,胡昌盛,李付远,陈东海,童丽军,梅益斌,急性冠脉综合征患者血清内皮素-1与C反应蛋白的变化及PCI的影响观察.心脑血管病防治2011年第1期32-34.
16.梁伟东曾波,阿托伐他汀对急性冠脉综合征患者血清内皮素和血管细胞黏附分子-1的影响.《现代预防医学》2010年第12期2373-2374.
17.戎梦瑶,朵瑞雪,朱平,王聪华,汪莉,樊春梅,王彦宏,细胞亲环素A对单核来源泡沫细胞功能的影响.细胞与分子免疫学杂志2011年第5期515-518.
18.王朝富,王培书,彭超,刘全义,一次性阿托伐他汀强化治疗对急性冠脉综合征患者PCI术后血清hs-CRP和MMP-9水平的影响.实用医学杂志2011年第3期488-490.
19.张田田,张俊峰,亲环素A及其受体CD147对动脉粥样硬化的影响.上海交通大学学报(医学版)2011年第12期1778-1781.
20.葛良清周怀能,替罗非班对急性冠脉综合征患者PCI术后心功能及炎症因子的影响.《中国现代医学杂志》2011年第30期3834-3836.
21. J.W. Dear, K.J. Simpson, M.P.J. Nicolai, J.H. Catterson, J. Street, T. Huizinga,D.G. Craig, K. Dhaliwal, S. Webb, D.N. Bateman, and D.J. Webb, Cyclophilin AIs a Damage-Associated Molecular Pattern Molecule That MediatesAcetaminophen-Induced Liver Injury. J Immunol.2011;187(6):3347-52.
22.周波,罗玉萍,龚熹,李思光,亲环蛋白的结构、细胞定位和生物学功能.细胞生物学杂志2008年第3期291-296.
23.郭琰,廖端芳,庹勤慧, Cyclophilin A在心脑血管疾病方面的研究进展.现代生物医学进展2009年第17期3384-3386.
24. C. Zhu, X. Wang, J. Deinum, Z. Huang, J. Gao, N. Modjtahedi, M.R. Neagu, M.Nilsson, P.S. Eriksson, H. Hagberg, J. Luban, G. Kroemer, and K. Blomgren,Cyclophilin A participates in the nuclear translocation of apoptosis-inducingfactor in neurons after cerebral hypoxia-ischemia. J Exp Med.2007;204:1741–1748.
25. K. Satoh, T. Matoba, J. Suzuki, M.R. O'Dell, P. Nigro, Z. Cui, A. Mohan, S. Pan,L. Li, Z.-G. Jin, C. Yan, J.-i. Abe, and B.C. Berk, Cyclophilin A MediatesVascular Remodeling by Promoting Inflammation and Vascular Smooth MuscleCell Proliferation. Circulation.2008;117(24):3088-98.
26.郭紫芬,廖端芳, Cyclophilin A触发荷脂细胞免疫反应与胆固醇跨膜转运的关系.中国动脉硬化杂志2009年第7期615.
27.何瑾,周志刚,王春燕,尹凯,孟军,涂玉林,亲环素A在ox-LDL诱导的血管平滑肌细胞泡沫化过程中的作用.南华大学学报(医学版)(2009).
28.廖端芳,庹勤慧,郭琰, Cyclophilin A通过调控炎症/免疫反应介导动脉粥样硬化.中国动脉硬化杂志2009年第7期614-614.
1. N. Nagradova, Peptidyl-prolyl Cis/trans Isomerase Activity In The FunctioningOf Native Folded Proteins. WebmedCentral MOLECULAR BIOLOGY1WMC00965.
2. D. Fruman, C. Klee, B. Bierer, and S. Burakoff, Calcineurin Phosphatase Activityin T Lymphocytes is Inhibited by FK506and Cyclosporin A. PNAS89(1992)3686-3690.
3. W. Rosamond, K. Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. Haase, M.Ho, V. Howard, B. Kissela, S. Kittner, D. Lloyd-Jones, M. McDermott, J. Meigs,C. Moy, G. Nichol, C.J. O'Donnell, V. Roger, J. Rumsfeld, P. Sorlie, J. Steinberger,T. Thom, S. Wasserthiel-Smoller, Y. Hong, f.t.A.H.A.S. Committee, and StrokeStatistics Subcommittee, Heart Disease and Stroke Statistics--2007Update: AReport From the American Heart Association Statistics Committee and StrokeStatistics Subcommittee. Circulation115(2007) e69-171.
4. R. Ross, Atherosclerosis--An Inflammatory Disease. N. Engl. J. Med.340(1999)115-126.
5. J. Liu, J. Farmer, W. Lane, J. Friedman, I. Weissman, and S. Schreiber,Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506complexes. Cell66(1991)807-15.
6. Galat, Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem216(1993)689-707.
7. Sherry, N. Yarlett, A. Strupp, and A. Cerami, Identification of Cyclophilin as aProinflammatory Secretory Product of Lipopolysaccharide-ActivatedMacrophages. PNAS89(1992)3511-3515.
8. Q. Xu, M. Leiva, S. Fischkoff, R. Handschumacher, and C. Lyttle, Leukocytechemotactic activity of cyclophilin. J. Biol. Chem.267(1992)11968-11971.
9. J. Rengarajan, S. Szabo, and L. Glimcher, Transcriptional regulation of Th1/Th2polarization. Immunol Today21(2000)479-83.
10. Miller, H. Wilcox, Z. Lai, and L. Berg, Signaling through Itk promotes T helper2differentiation via negative regulation of T-bet. Immunity21(2004)67-80.
11. J. Kofron, P. Kuzmic, V. Kishore, E. Colon-Bonilla, and D. Rich, Determinationof kinetic constants for peptidyl prolyl cis-trans isomerases by an improvedspectrophotometric assay. Biochemistry30(1991)6127-34.
12. J. Frostegard, A. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson, andG. Hansson, Cytokine expression in advanced human atherosclerotic plaques:dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.Atherosclerosis145(1999)33-43.
13. E.S. Hwang, S.J. Szabo, P.L. Schwartzberg, and L.H. Glimcher, T Helper CellFate Specified by Kinase-Mediated Interaction of T-bet with GATA-3. Science307(2005)430-433.
14. R. Mallis, K. Brazin, D. Fulton, and A. Andreotti, Structural characterization of aproline-driven conformational switch within the Itk SH2domain. Nat Struct Biol9(2002)900-5.
1. Girn HR, Orsi NM, Homer-Vanniasinkam S. An overview of cytokineinteractions in atherosclerosis and implications for peripheral arterial disease.Vasc Med2007;12(4):299-309.
2. Dinarello CA. The role of the interleukin-1-receptor antagonist in blockinginflammation mediated by interleukin-1. N Engl J Med2000;343(10):732-734.
3. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differentialeffects of interleukin-1receptor antagonist and tumor necrosis factor bindingprotein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation1998;97(3):242-244.
4. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, Pelli G, JamesRW, Mach F, Gabay C. Interleukin-1plays a major role in vascular inflammationand atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res2005;66(3):583-593.
5. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y,Ohsuzu F. Lack of interleukin-1receptor antagonist modulates plaquecomposition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol2004;24(6):1068-1073.
6. Isoda K, Ohsuzu F. The effect of interleukin-1receptor antagonist on arteries andcholesterol metabolism. J Atheroscler Thromb2006;13(1):21-30.
7. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18enhancesatherosclerosis in apolipoprotein E(-/-) mice through release ofinterferon-gamma. Circ Res2002;90(2):E34-38.
8. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S, Bayard F,Hansson GK. Reduced atherosclerosis in interleukin-18deficient apolipoproteinE-knockout mice. Cardiovasc Res2003;59(1):234-240.
9. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y,Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18binding protein signalingmodulates atherosclerotic lesion development and stability. Circ Res2001;89(7):E41-45.
10. Upadhya S, Mooteri S, Peckham N, Pai RG. Atherogenic effect of interleukin-2and antiatherogenic effect of interleukin-2antibody in apo-E-deficient mice.Angiology2004;55(3):289-294.
11. Walch L, Massade L, Dufilho M, Brunet A, Rendu F. Pro-atherogenic effect ofinterleukin-4in endothelial cells: modulation of oxidative stress, nitric oxide andmonocyte chemoattractant protein-1expression. Atherosclerosis2006;187(2):285-291.
12. George J, Mulkins M, Shaish A, Casey S, Schatzman R, Sigal E, Harats D.Interleukin (IL)-4deficiency does not influence fatty streak formation inC57BL/6mice. Atherosclerosis2000;153(2):403-411.
13. Davenport P, Tipping PG. The role of interleukin-4and interleukin-12in theprogression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol2003;163(3):1117-1125.
14. Vadiveloo PK, Stanton HR, Cochran FW, Hamilton JA. Interleukin-4inhibitshuman smooth muscle cell proliferation. Artery1994;21(3):161-181.
15. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA. Stat6activationis essential for interleukin-4induction of P-selectin transcription in humanumbilical vein endothelial cells. Arterioscler Thromb Vasc Biol1999;19(6):1421-1429.
16. King VL, Cassis LA, Daugherty A. Interleukin-4does not influence developmentof hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice.Am J Pathol2007;171(6):2040-2047.
17. George J, Shoenfeld Y, Gilburd B, Afek A, Shaish A, Harats D. Requisite role forinterleukin-4in the acceleration of fatty streaks induced by heat shock protein65or Mycobacterium tuberculosis. Circ Res2000;86(12):1203-1210.
18. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: acomprehensive review of studies in mice. Cardiovasc Res2008;79(3):360-376.
19. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, CurtissLK, Corr M, Witztum JL. IL-5links adaptive and natural immunity specific forepitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest2004;114(3):427-437.
20. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM,Lusis AJ. Induction of endothelial cell expression of granulocyte andmacrophage colony-stimulating factors by modified low-density lipoproteins.Nature1990;344(6263):254-257.
21. Shaposhnik Z, Wang X, Weinstein M, Bennett BJ, Lusis AJ. Granulocytemacrophage colony-stimulating factor regulates dendritic cell content ofatherosclerotic lesions. Arterioscler Thromb Vasc Biol2007;27(3):621-627.
22. Shindo J, Ishibashi T, Yokoyama K, Nakazato K, Ohwada T, Shiomi M,Maruyama Y. Granulocyte-macrophage colony-stimulating factor prevents theprogression of atherosclerosis via changes in the cellular and extracellularcomposition of atherosclerotic lesions in watanabe heritable hyperlipidemicrabbits. Circulation1999;99(16):2150-2156.
23. Haghighat A, Weiss D, Whalin MK, Cowan DP, Taylor WR. Granulocytecolony-stimulating factor and granulocyte macrophage colony-stimulating factorexacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation2007;115(15):2049-2054.
24. Ditiatkovski M, Toh BH, Bobik A. GM-CSF deficiency reduces macrophagePPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice.Arterioscler Thromb Vasc Biol2006;26(10):2337-2344.
25. Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A, Lambert D,Visvikis S. IL-6, TNF-α-alpha and atherosclerosis risk indicators in a healthyfamily population: the STANISLAS cohort. Atherosclerosis2003;170(2):277-283.
26. von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins inatherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev2003;55(1):133-166.
27. Klouche M, Rose-John S, Schmiedt W, Bhakdi S. Enzymatically degraded,nonoxidized LDL induces human vascular smooth muscle cell activation, foamcell transformation, and proliferation. Circulation2000;101(15):1799-1805.
28. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6exacerbatesearly atherosclerosis in mice. Arterioscler Thromb Vasc Biol1999;19(10):2364-2367.
29. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F.Involvement of interleukin-6in atherosclerosis but not in the prevention of fattystreak formation by17beta-estradiol in apolipoprotein E-deficient mice.Atherosclerosis2001;156(2):315-320.
30. Schieffer B, Selle T, Hilfiker A, Hilfiker-Kleiner D, Grote K, Tietge UJ,Trautwein C, Luchtefeld M, Schmittkamp C, Heeneman S, Daemen MJ, DrexlerH. Impact of interleukin-6on plaque development and morphology inexperimental atherosclerosis. Circulation2004;110(22):3493-3500.
31. Song L, Schindler C. IL-6and the acute phase response in murine atherosclerosis.Atherosclerosis2004;177(1):43-51.
32. Trinchieri G. Interleukin-12and the regulation of innate resistance and adaptiveimmunity. Nat Rev Immunol2003;3(2):133-146.
33. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, vanSnick J, Kuiper J. Blockade of interleukin-12function by protein vaccinationattenuates atherosclerosis. Circulation2005;112(7):1054-1062.
34. Baidya SG, Zeng QT, Wang X, Guo HP. T helper cell related interleukins and theangiographic morphology in unstable angina. Cytokine2005;30(5):303-310.
35. Steppich BA, Moog P, Matissek C, Wisniowski N, Kuhle J, Joghetaei N,Neumann FJ, Schomig A, Ott I. Cytokine profiles and T cell function in acutecoronary syndromes. Atherosclerosis2007;190(2):443-451.
36. Harvey EJ, Ramji DP. Interferon-gamma and atherosclerosis: pro-oranti-atherogenic? Cardiovasc Res2005;67(1):11-20.
37. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatorypathways. Physiol Rev2006;86(2):515-581.
38. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, Kim DW, Kim YK, RoHK, Shong M. Statin inhibits interferon-gamma-induced expression ofintercellular adhesion molecule-1(ICAM-1) in vascular endothelial and smoothmuscle cells. Exp Mol Med2002;34(6):451-461.
39. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gammaenhances atherosclerosis in apolipoprotein E-/-mice. Am J Pathol2000;157(6):1819-1824.
40. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exertsgender-specific effects on atherogenesis in apolipoprotein E-/-mice. J InterferonCytokine Res2002;22(6):661-670.
41. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH.Influence of interferon-gamma on the extent and phenotype of diet-inducedatherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol2003;23(3):454-460.
42. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gammapotentiates atherosclerosis in ApoE knock-out mice. J Clin Invest1997;99(11):2752-2761.
43. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detectionand localization of tumor necrosis factor in human atheroma. Am J Cardiol1990;65(5):297-302.
44. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis ofatherosclerosis. Thromb Haemost2002;88(4):554-567.
45. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhancedexpression of vascular matrix metalloproteinases induced in vitro by cytokinesand in regions of human atherosclerotic lesions. Ann N Y Acad Sci1995;748:501-507.
46. Schreyer SA, Vick CM, LeBoeuf RC. Loss of lymphotoxin-alpha but not tumornecrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem2002;277(14):12364-12368.
47. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, Saito K, Sekikawa K,Seishima M. Disruption of tumor necrosis factor-alpha gene diminishes thedevelopment of atherosclerosis in ApoE-deficient mice. Atherosclerosis2005;180(1):11-17.
48. Boesten LS, Zadelaar AS, van Nieuwkoop A, Gijbels MJ, de Winther MP,Havekes LM, van Vlijmen BJ. Tumor necrosis factor-alpha promotesatherosclerotic lesion progression in APOE*3-Leiden transgenic mice.Cardiovasc Res2005;66(1):179-185.
49. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in micelacking tumor necrosis factor receptor p55. J Biol Chem1996;271(42):26174-26178.
50. Shin WS, Szuba A, Rockson SG. The role of chemokines in humancardiovascular pathology: enhanced biological insights. Atherosclerosis2002;160(1):91-102.
51. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease.Circ Res2004;95(9):858-866.
52. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue ofthe IL-8receptor CXCR-2mediates the accumulation of macrophages inatherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest1998;101(2):353-363.
53. Martins TB, Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Roberts WL.Risk factor analysis of plasma cytokines in patients with coronary artery diseaseby a multiplexed fluorescent immunoassay. Am J Clin Pathol2006;125(6):906-913.
54. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8mediates downregulation of tissue inhibitor of metalloproteinase-1expression incholesterol-loaded human macrophages: relevance to stability of atheroscleroticplaque. Circulation1999;99(3):420-426.
55. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F,Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A.Protective role of interleukin-10in atherosclerosis. Circ Res1999;85(8):e17-24.
56. Namiki M, Kawashima S, Yamashita T, Ozaki M, Sakoda T, Inoue N, Hirata K,Morishita R, Kaneda Y, Yokoyama M. Intramuscular gene transfer ofinterleukin-10cDNA reduces atherosclerosis in apolipoprotein E-knockout mice.Atherosclerosis2004;172(1):21-29.
57. Anguera I, Miranda-Guardiola F, Bosch X, Filella X, Sitges M, Marin JL, BetriuA, Sanz G. Elevation of serum levels of the anti-inflammatory cytokineinterleukin-10and decreased risk of coronary events in patients with unstableangina. Am Heart J2002;144(5):811-817.
58. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of theantiinflammatory cytokine interleukin-10are decreased in patients with unstableangina. Circulation2001;104(7):746-749.
59. Metcalfe JC, Grainger DJ. Transforming growth factor-beta and the protectionfrom cardiovascular injury hypothesis. Biochem Soc Trans1995;23(2):403-406.
60. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, sogood for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol2004;24(3):399-404.
61. Yamagami S, Yokoo S, Mimura T, Amano S. Effects of TGF-beta2on immuneresponse-related gene expression profiles in the human corneal endothelium.Invest Ophthalmol Vis Sci2004;45(2):515-521.
62. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB,Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta1nullmutation in mice causes excessive inflammatory response and early death. ProcNatl Acad Sci U S A1993;90(2):770-774.
63. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R,Fradelizi D, Tedgui A. Inhibition of transforming growth factor-beta signalingaccelerates atherosclerosis and induces an unstable plaque phenotype in mice.Circ Res2001;89(10):930-934.
64. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE,Daemen MJ. Transforming growth factor-beta mediates balance betweeninflammation and fibrosis during plaque progression. Arterioscler Thromb VascBiol2002;22(6):975-982.